

Sent by email

British Uro-Oncology Group (BUG) Executive Committee  
Barley Mow Centre  
10 Barley Mow Passage  
London W4 4 PH

25 June 2014

Dear [REDACTED]

**Final Appraisal Determination: Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen**

Thank you for your letter dated 17 June 2014. This letter represents my final decision on initial scrutiny.

**1.1 Inclusion of paragraph 1.2 of the FAD is not fair**

My view remains that this is not a valid ground of appeal, for the reasons set out in my previous letter.

This is the final decision on initial scrutiny.

Yours sincerely,

Dr Maggie Helliwell  
Vice Chair of NICE  
National Institute for Health and Care Excellence